-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic kidney disease (CKD) undergoing dialysis treatment of most patients with anemia, resulting in patient quality of life is reduced, frequent blood transfusions and cardiac vascular events increased risk
.
Previous studies have found that traditional erythropoietin (ESAs) treatment is associated with an increased risk of cardiovascular events in patients, while recombinant human erythropoietin and its derivatives may increase the risk of stroke, myocardial infarction , thrombosis, and tumor in patients
Quality of life of heart vascular events myocardial infarction thrombosis recently researchers examined Daprodustat anemia of CKD patients undergoing dialysis efficacy and safety
In this randomized, open phase 3 trial, CKD patients undergoing dialysis with a hemoglobin level of 8.
0 to 11.
5 g/dL were randomized to receive Daprodustat or ESAs (hemodialysis patients received epoetin alfa, and peritoneal dialysis patients received alfada Bettin)
.
The primary endpoint of the study was the average change in hemoglobin levels from baseline examination to weeks 28-52 and the first major adverse cardiovascular event (combination of death from any cause, non-fatal myocardial infarction, or non-fatal stroke)
2964 patients participated in the study, and the average baseline hemoglobin level was 10.
4 g/dL
.
The average change in hemoglobin level from baseline inspection to week 28 to week 52 in the Daprodustat group was 0.
The average change in hemoglobin levels in the Daprodustat group from baseline inspection to week 28 to week 52 was 0.
Changes in hemoglobin levels between groups
Changes in hemoglobin levels between groups Changes in hemoglobin levels between groupsIn CKD patients undergoing dialysis, Daprodustat is comparable to erythropoiesis agents in improving hemoglobin levels and cardiovascular outcomes
In CKD patients undergoing dialysis, Daprodustat is equivalent to erythropoiesis agents in increasing hemoglobin levels and cardiovascular outcomes.
Original source:
Ajay K.
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Leave a message here
